Our Pricing

Complete Guide to Getting Mounjaro On NHS For Weight Loss

Published on: June 03, 2026

Understanding whether you can access Mounjaro on NHS for weight loss depends on specific eligibility criteria and local commissioning decisions. While Mounjaro (tirzepatide) is MHRA-licensed for weight management in the UK, NHS availability remains extremely limited, with most patients exploring private prescription options through registered UK pharmacies like Cured Pharmacy.

Current NHS Status of Mounjaro for Weight Loss

Mounjaro received its UK marketing authorisation from the MHRA in November 2023 for weight management in adults with obesity or overweight with weight-related comorbidities [1]. However, NICE (National Institute for Health and Care Excellence) has not yet issued full guidance recommending Mounjaro for routine NHS prescription for weight loss as of 2025.

This means that while Mounjaro is a licensed medication in the UK, NHS access remains severely restricted. Most Clinical Commissioning Groups (CCGs) and Integrated Care Boards (ICBs) do not routinely fund tirzepatide for weight management, even when patients meet clinical criteria. The few NHS prescriptions issued typically occur through specialist weight management services with strict eligibility thresholds.

In contrast, Mounjaro is available through private prescription from UK-registered pharmacies following clinical assessment by a UK prescriber. At Cured Pharmacy, patients can access genuine UK-licensed Mounjaro from £124.99 following a free online consultation completed in under three minutes.

NHS Eligibility Criteria for Weight Loss Medications

When NHS funding is available for weight loss medications, eligibility typically requires a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [2]. Patients must also demonstrate commitment to lifestyle modifications including dietary changes and increased physical activity.

Even when meeting these clinical thresholds, NHS access to Mounjaro specifically remains exceptional rather than routine. Most NHS weight management programmes currently offer older medications like Orlistat as first-line treatment, with GLP-1 receptor agonists reserved for specialist services. Waiting times for NHS specialist weight management clinics frequently exceed 12-18 months in many regions.

Private prescription through a UK-registered pharmacy offers an alternative pathway for eligible patients. At Cured Pharmacy, our UK prescribers assess the same clinical criteria during your online consultation, ensuring safe and appropriate prescribing based on your medical history, current medications, and weight management goals.

What NHS Weight Management Services Actually Offer

NHS weight management services typically provide a tiered approach starting with behavioural support, dietary counselling, and exercise programmes. Pharmacological intervention is usually reserved for patients who have not achieved adequate weight loss through lifestyle measures alone after three to six months.

Where medication is prescribed, Orlistat remains the most commonly offered NHS option due to its lower cost. Newer GLP-1 receptor agonists like Wegovy have limited availability through specialist services only, and Mounjaro on NHS for weight loss remains exceptionally rare outside research settings or individual funding requests.

How Mounjaro Works: The Dual-Action Mechanism

Mounjaro contains tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed for weight management [1]. This dual mechanism distinguishes it from single-pathway medications like semaglutide (Wegovy), potentially offering enhanced efficacy.

Tirzepatide works by activating two complementary hormone pathways that regulate appetite, food intake, and glucose metabolism. GLP-1 receptor activation reduces appetite and slows gastric emptying, whilst GIP receptor activation may enhance insulin secretion and improve fat metabolism. This dual action produced superior weight loss outcomes in head-to-head clinical trials.

In the SURMOUNT-1 trial, participants receiving the 15mg tirzepatide dose achieved an average weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. The SURMOUNT-3 trial demonstrated that patients maintained an average 25.3% total body weight reduction when continuing tirzepatide after initial weight loss [3]. These results represent some of the highest efficacy data for any currently licensed weight management medication.

Private Prescription Options: Accessing Mounjaro Through UK Pharmacies

Given limited NHS availability, most UK patients access Mounjaro through private prescription from registered online pharmacies. This pathway requires a clinical consultation with a UK prescriber who assesses your suitability based on medical history, current health status, and weight management objectives.

At Cured Pharmacy (GPhC Registration 9012511), our process ensures clinical safety whilst offering convenient access. Your free online consultation takes under three minutes and is reviewed by our UK-registered clinical team. If Mounjaro is deemed appropriate for you, your prescription is fulfilled with genuine UK-licensed medication, dispensed by our superintendent pharmacist Tarun Kumar (GPhC 2233073).

Transparent pricing means you see costs upfront before consultation. Mounjaro starts from £124.99, with final pricing determined by your prescribed dose. All medications are supplied in discreet packaging with next-day delivery options available across the UK.

Clinical Assessment Requirements

Whether accessing Mounjaro through NHS or private prescription, the same clinical safety standards apply. UK prescribers must assess your BMI, weight-related health conditions, previous weight loss attempts, current medications, and any contraindications before prescribing tirzepatide.

Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or previous serious hypersensitivity to tirzepatide. Your prescriber will also review medications that may interact with GLP-1 receptor agonists, particularly insulin and sulfonylureas which may require dose adjustments.

Comparing Mounjaro to Other Weight Loss Treatments

Understanding how Mounjaro compares to alternative weight loss medications helps inform treatment decisions. Wegovy (semaglutide) is another GLP-1 receptor agonist licensed for weight management, demonstrating average weight loss of 15% in the STEP-1 trial [4]. Saxenda (liraglutide) is a daily injection producing average weight loss of 8% in clinical trials [5].

Oral medications like Orlistat work through a different mechanism, blocking fat absorption in the intestine. Orlistat typically produces more modest weight loss of 3-5% but is available at a lower price point and may suit patients who prefer not to use injectable medications.

Your choice between treatments depends on several factors including efficacy targets, administration preference (weekly versus daily injections, or oral tablets), side effect profiles, and cost considerations. At Cured Pharmacy, our prescribers discuss these options during your consultation to identify the most appropriate treatment for your circumstances.

Injectable vs Oral Weight Loss Options

Injectable GLP-1 receptor agonists like Mounjaro, Wegovy, and Saxenda generally demonstrate superior efficacy compared to oral alternatives, though they require patient comfort with subcutaneous injection. Most patients find the pre-filled pen devices straightforward to use after initial training.

Oral options including Orlistat and the newly available Wegovy oral tablets (semaglutide pill) may appeal to patients who prefer not to inject. Orlistat requires dietary fat restriction to minimise gastrointestinal side effects, whilst oral semaglutide must be taken on an empty stomach with specific timing requirements.

What to Expect: Treatment Journey and Monitoring

Mounjaro treatment follows a gradual dose escalation schedule to minimise gastrointestinal side effects. Treatment typically begins with 2.5mg weekly for four weeks, increasing to 5mg for four weeks, then potentially escalating to 7.5mg, 10mg, 12.5mg, or 15mg based on efficacy and tolerability [1].

Common side effects include nausea, diarrhoea, reduced appetite, vomiting, and constipation, particularly during dose escalation phases. These effects are usually mild to moderate and diminish over time as your body adjusts to the medication. Staying well-hydrated and eating smaller, more frequent meals can help manage initial side effects.

Regular monitoring is essential during Mounjaro treatment. Your prescriber will assess weight loss progress, side effects, and any changes in health status through follow-up consultations. Most patients are reviewed monthly during the first three months, then quarterly once established on a stable dose. Treatment continuation depends on achieving meaningful weight loss, typically defined as at least 5% body weight reduction within the first 12-16 weeks.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. National Institute for Health and Care Excellence. (2014). Weight management: lifestyle services for overweight or obese adults (PH53). NICE guideline. https://www.nice.org.uk/guidance/ph53 [accessed 13 August 2026]
3. Aronne, L. J., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945 [accessed 13 August 2026]
4. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss medications should be used alongside lifestyle modifications including dietary changes and increased physical activity.